{"entity":{"id":"nct06210360","kind":"trial","name":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","aka":[],"tldr":"A phase 2 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Changhai Hospital, not yet recruiting.","summary":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX is a phase 2, randomised interventional study registered as NCT06210360 by Changhai Hospital, with a registry enrolment figure of 134 participants, started 2024-02-01 and due to reach its primary completion in 2025-04-01. Interventions recorded: Irinotecan liposome injection; Oxaliplatin; 5-FU; LV. Conditions listed: Pancreatic Cancer. Primary outcome: 2-year Overall Survival Rate. Pancreatic eligibility wording from the registry: \"Histologically or cytologically proven pancreatic ductal adenocarcinoma\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06210360","url":"https://clinicaltrials.gov/study/NCT06210360"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["liposomal-irinotecan","capox","fluorouracil","leucovorin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06210360","phase":"2","setting":"NALIRIFOX as Perioperative Treatment in Patients With High-risk Resectable Pancreatic Cancer : a Multicenter, Randomized, Open-label Trial","sponsor":"Changhai Hospital","enrolled":134,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06210360/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}